Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data

David A Jolliffe PhD^{1,2†} Carlos A Camargo Jr MD³ John D Sluyter PhD⁴ Mary Aglipay MSc⁵ John F Aloia MD⁶ Peter Bergman MD⁸ Heike A. Bischoff-Ferrari MD⁹ Arturo Borzutzky MD¹⁰ Vadim Y Bubes MD³⁹ Camilla T Damsgaard PhD¹¹ Francine Ducharme³⁸ Gal Dubnov-Raz MD¹² Susanna Esposito MD¹³ Davaasambuu Ganmaa PhD⁷ Clare Gilham MSc¹⁴ Adit A Ginde MD¹⁵ Inbal Golan-Tripto MD¹⁶ Emma C Goodall PhD¹⁷ Cameron C Grant MD¹⁸ Christopher J Griffiths D Phil^{1,2} Anna Maria Hibbs MD^{19,20} Wim Janssens MD ²¹ Anuradha Vaman Khadilkar MD²² Ilkka Laaksi MD²³ Margaret T Lee MD²⁴ Mark Loeb MD²⁵ Jonathon L Maguire MD⁵ Paweł Majak MD²⁶ Semira Manaseki-Holland PhD²⁸ JoAnn E Manson MD³⁹

1

David T Mauger PhD²⁷ David R Murdoch MD²⁹ Akio Nakashima MD³⁰ Rachel E Neale PhD³¹ Hai Pham MPH³¹ Christine Rake BSc¹⁴ Judy R Rees BM, BCh³² Jenni Rosendahl MD³³ Robert Scragg MD⁴ Dheeraj Shah MD³⁴ Yoshiki Shimizu PhD³⁵ Steve Simpson-Yap MD³⁶ Geeta Trilok Kumar PhD³⁷ Mitsuyoshi Urashima MD³⁰ Adrian R Martineau PhD^{1,2†}

¹Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK

²Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK

³Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

⁴School of Population Health, University of Auckland, Auckland, New Zealand
⁵Department of Pediatrics, St Michael's Hospital, Toronto, Ontario, Canada
⁶Bone Mineral Research Center, Winthrop University Hospital, Mineola, NY, USA
⁷Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
⁸Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
⁹Department of Geriatric Medicine and Aging Research, University Hospital Zurich, Zurich, Switzerland
¹⁰Department of Pediatric Infectious Diseases and Immunology, School of Medicine,

Pontificia Universidad Católica de Chile, Santiago, Chile

¹¹Department of Nutrition, Exercise and Sports, University of Copenhagen,

Frederiksberg, Denmark

¹²Exercise, Lifestyle and Nutrition Clinic, Edmond and Lily Safra Children's Hospital,

Tel Hashomer, Israel

¹³Paediatric Clinic, Department of Medicine and Surgery, University of Parma, Parma, Italy

¹⁴Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

¹⁵Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA

¹⁶Saban Pediatric Medical Center, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University, Beer Sheva, Israel

¹⁷Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada

¹⁸Department of Paediatrics: Child & Youth Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

¹⁹Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA

²⁰University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH, USA
²¹Universitair ziekenhuis Leuven, Leuven, Belgium

²²Hirabai Cowasji Jehangir Medical Research Institute, Maharashtra, India

²³Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland

²⁴Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University Medical Center, New York, NY USA

²⁵Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada

²⁶Department of Pediatric Pulmonology, Medical University of Lodz, Lodz, Poland
 ²⁷Department of Statistics, The Pennsylvania State University, Hershey, PA, USA

²⁸Department of Public Health, Epidemiology and Biostatistics, Institute of Applied Health Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

²⁹Department of Pathology, University of Otago, Christchurch, New Zealand

³⁰Jikei University School of Medicine, Tokyo, Japan

³¹Population Health Department, QIMR Berghofer Medical Research Institute, Queensland, Australia

³²Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

³³Children's Hospital, Pediatric Research Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

³⁴Department of Paediatrics, University College of Medical Sciences, Delhi, India

³⁵FANCL Research Institute, FANCL Corporation, Yokohama, Japan

³⁶Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia

³⁷Institute of Home Economics, University of Delhi, New Delhi, India

³⁸Departments of Paediatrics and of Social and Preventive Medicine, University of Montréal, Canada

³⁹Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

† To whom correspondence should be addressed at the Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, London E1 2AT, UK

Tel: +44 207 882 2551 | Fax: +44 207 882 2552 | Email: <u>d.a.jolliffe@qmul.ac.uk</u> or <u>a.martineau@qmul.ac.uk</u>

ABSTRACT

Background: A 2021 meta-analysis of 37 randomised controlled trials (RCTs) of vitamin D supplementation for prevention of acute respiratory infections (ARI) revealed a statistically significant protective effect of the intervention (odds ratio [OR] 0.92, 95% confidence interval [CI] 0.86 to 0.99). Since then, 6 eligible RCTs have completed, including one large trial (n=15,804).

Methods: Updated systematic review and meta-analysis of data from RCTs of vitamin D for ARI prevention using a random effects model. Sub-group analyses were done to determine whether effects of vitamin D on risk of ARI varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, dosing regimen or age. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and the ClinicalTrials.gov were searched between May 2020 (previous search) and April 2024. No language restrictions were imposed. Double-blind RCTs supplementing vitamin D for any duration, with placebo or low-dose vitamin D control, were eligible if approved by Research Ethics Committee and if ARI incidence was collected prospectively and pre-specified as an efficacy outcome. Aggregate data, stratified by baseline 25(OH)D concentration and age, were obtained from study authors. The study was registered with PROSPERO (no. CRD42024527191).

Findings: We identified 6 new RCTs (19,337 participants). Data were obtained for 16,086 (83.2%) participants in 3 new RCTs and combined with data from 48,488 participants in 43 previously identified RCTs. For the primary comparison of any vitamin D vs. placebo, the intervention did not significantly affect overall ARI risk (OR 0.94, 95% CI 0.88 to 1.00, P=0.057; 40 studies; I² 26.4%). Pre-specified subgroup analysis did not reveal evidence of effect modification by age, baseline vitamin D status, or dosing regimen. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (OR 0.96, 95% CI 0.90 to 1.04; 38 studies; I² 0.0%). A funnel plot showed left-sided asymmetry (P=0.002, Egger's test).

Interpretation: This updated meta-analysis yielded a similar point estimate for the overall effect of vitamin D supplementation on ARI risk to that obtained previously, but

the 95% CI for this effect estimate now spans 1.00, indicating no statistically significant protection.

Funding: None

Research in context

Evidence before this study

We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and the ClinicalTrials.gov registry from 1st May 2020 (date of our previous search) to 30th April 2024 for randomised controlled trials and meta-analyses of randomised controlled trials evaluating effectiveness of vitamin D supplementation for the prevention of acute respiratory infections. Our previous meta-analysis of 43 randomised controlled trials (RCTs) of vitamin D supplementation for prevention of acute respiratory infections (ARI) conducted in 2021 revealed a statistically significant protective effect of the intervention (OR 0.92, 95% CI 0.86 to 0.99). A further 6 eligible RCTs, contributing data from 19,337 participants have now completed, including one large trial (n=15,804).

Added value of this study

Our meta-analysis of aggregate data from 64,086 participants in 46 randomised controlled trials, stratified by baseline 25(OH)D concentration and age, provides an updated estimate of the protective effects of vitamin D against acute respiratory infection overall (OR 0.94, 95% CI 0.88 to 1.00), and in sub-groups defined by baseline vitamin D status, age, and dosing frequency, amount and duration.

Implications of all the available evidence

Updated meta-analysis including the latest available RCT data shows no statistically significant protective effect of vitamin D supplementation against ARI, either overall or in sub-group analyses.

Introduction

The contribution of acute respiratory infections (ARI) to global morbidity and mortality, with consequent strain on healthcare systems, remains an ongoing problem in the post-COVID pandemic era. Evidence indicating that vitamin D supplementation could reduce risk of ARI arises from laboratory studies which show that vitamin D metabolites support innate immune responses to respiratory viruses,¹ together with observational studies reporting independent associations of low circulating levels of 25-hydroxyvitamin D (25[OH]D, the widely accepted biomarker of vitamin D status) and increased risk of ARI.^{2,3}

Randomised controlled trials (RCTs) of vitamin D for the prevention of ARI have produced heterogeneous results, with some showing protection, and others reporting null findings. We previously meta-analysed aggregate data from 48,488 participants in 43 RCTs,⁴⁻⁴⁶ and showed a modest protective overall effect that was stronger in trials which administered vitamin D in daily, that used doses of 400-1000 IU/day, were up to 12 months in length, and that were conducted among participants aged 1.00 to 15.99 years at enrolment.⁴⁷ Since the date of our previous literature search (May 2020), 6 RCTs with 19,337 participants fulfilling the same eligibility criteria have been completed. We therefore sought data from these recent studies for inclusion in an updated meta-analysis of stratified aggregate data (trial-level, stratified by baseline vitamin D status and age) to determine whether vitamin D reduced ARI risk overall, and to evaluate whether effects of vitamin D on ARI risk varied according to baseline 25(OH)D concentration, dosing regimen (frequency, dose size, and trial duration) or age at enrolment.

Methods

Protocol, Registration and Ethical Approvals

Methods were pre-specified in a protocol that was registered with the PROSPERO International Prospective Register of Systematic Reviews (<u>click here</u>). Details of Research Ethics Committee approvals to conduct this study are included in Supplementary Material (Section 4).

Eligibility Criteria

Double-blind randomised controlled trials of supplementation with vitamin D_3 , vitamin D_2 or 25(OH)D of any duration, with a placebo or blinded low-dose vitamin D control, were eligible for inclusion if they had been approved by a Research Ethics Committee and if data on incidence of ARI were collected prospectively and pre-specified as an efficacy outcome. The latter requirement was imposed to minimise misclassification bias (prospectively designed instruments to capture ARI events were deemed more likely to be sensitive and specific for this outcome). Studies reporting results of long-term follow-up of primary RCTs were excluded.

Study Identification and Selection

Two investigators (ARM and DAJ) searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and the ClinicalTrials.gov registry using the electronic search strategies described in the Supplementary Material (Section 1). Searches were regularly updated up to and including 1st April 2024. No language restrictions were imposed. These searches were supplemented by searching review articles and reference lists of trial publications. Collaborators were asked if they knew of any additional eligible RCTs.

Data Collection Process and Definition of outcomes

Details of the data collection process can be found in Supplementary Material (Section 2). The primary outcome of the meta-analysis was the proportion of participants

experiencing one or more ARI, with the definition of ARI encompassing events classified as URI, LRI and ARI of unclassified location (i.e. infection of the upper and/or lower respiratory tract). Secondary outcomes were: incidence of URI and LRI, analysed separately; incidence of Emergency Department attendance and/or hospital admission for ARI; death due to ARI or respiratory failure; use of antibiotics to treat an ARI; absence from work or school due to ARI; incidence of serious adverse events; death due to any cause; and incidence of potential adverse reactions to vitamin D (hypercalcaemia and renal stones).

Risk of Bias Assessment for Individual Studies

We used the Cochrane Collaboration Risk of Bias tool⁴⁸ to assess the following variables: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, completeness of outcome data, evidence of selective outcome reporting, and other potential threats to validity. Study quality was assessed independently by two investigators (ARM and DAJ), except for the six trials for which DAJ and/or ARM were investigators, which were assessed by CAC and JDS. Discrepancies were resolved by consensus.

Synthesis Methods

Data were analysed by DAJ; results were checked and verified by JDS. Our metaanalysis approach followed published guidelines.⁴⁹ The primary comparison was of participants randomised to any vitamin D supplement vs. placebo: this was performed for all of the outcomes listed above. For trials that included higher-dose, lower-dose and placebo arms, data from higher-dose and lower-dose arms were pooled for analysis of the primary comparison. A secondary comparison of participants randomised to higher vs. lower doses of vitamin D was performed for the primary outcome only.

The log odds ratio and its standard error were calculated for each outcome within each trial from the proportion of participants experiencing one or more events in the intervention vs. control arm. For trials where randomisation was stratified by study site, proportions were corrected for clustering using published methods.⁵⁰ Proportions were then meta-analysed in a random effects model using the Metan package⁵¹ within STATA IC v14.2 to obtain a pooled odds ratio with a 95% confidence interval (CI) and a measure of heterogeneity summarized by the I² statistic and its corresponding P value.

Exploration of variation in effects

To explore reasons for heterogeneity of effect of the intervention between trials we performed a stratified analysis according to baseline vitamin D status (serum 25[OH]D <25 vs. 25-49.9 vs. 50-74.9 vs. \geq 75 nmol/L) and according to age at baseline (<1.00 vs. 1.00-15.99 vs. 16.00-64.99 vs. \geq 65.00 years). We also conducted sub-group analyses according to vitamin D dosing regimen (administration of daily vs. weekly vs. monthly or less frequent doses), dose size (daily equivalent <400 IU vs. 400-1000 IU vs. 1001-2000 IU vs. >2,000 IU), trial duration (\leq 12 months vs. >12 months) and presence of airway disease (trial restricted to participants with asthma vs. those restricted to participants with COPD vs. those in which participants without airway disease were eligible). The thresholds for baseline 25(OH)D concentration used in sub-group analyses were selected *a priori* on the basis that they represent cut-offs that are commonly used to distinguish profound vitamin D deficiency (<25 nmol/L), moderate vitamin D deficiency (25-49.9 nmol/L) and potentially sub-optimal vitamin D status (50-74.9 nmol/L).⁵²

To investigate factors associated with heterogeneity of effect between statistically significant subgroups of trials, we performed multivariable meta-regression analysis on trial-level characteristics, the full details of which is described in Supplementary Material (Section 5).

Quality Assessment Across Studies

For the primary analysis, the likelihood of publication bias was investigated through the construction of a contour-enhanced funnel plot.⁵³ We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias)⁵⁴ to assess the quality of the body of evidence contributing to analyses of the primary efficacy outcome and major secondary outcomes of our meta-analysis.

Sensitivity analyses

We conducted two exploratory sensitivity analyses for the primary comparison of the primary outcome: one excluded RCTs where risk of bias was assessed as being unclear, and the other excluded RCTs in which incidence of ARI was not the primary or co-primary outcome.

Exploratory analyses

Due to the relatively low level of heterogeneity between trials entering into the primary outcome model, we also estimated the overall primary outcome using a fixed effects model.

Role of the funding source

This study was conducted without external funding.

Results

Study selection and data obtained

The study selection process is illustrated in Figure 1. Our updated search (studies registered from 2nd May 2020 to 1st April 2024) identified a total of 1,107 studies that were assessed for eligibility, of which six studies with a total of 19,337 randomised participants fulfilled eligibility criteria. Studies for which full text was reviewed prior to exclusion due to ineligibility are listed in Table S1. All six of the eligible studies identified compared effects of a single vitamin D regimen vs. placebo only. Data for the primary outcome (proportion of participants in 3 studies^{14,55,56} and were added to our database of 43 previously identified eligible studies, described elsewhere,⁴⁷ bringing the total number of participants contributing data to analysis of our primary outcome to 64,086 out of 65,504 (97.8%) participants in 46 studies.

Study and participant characteristics

Characteristics of the 46 studies contributing data to this meta-analysis are presented in Table 1. Trials were conducted in 24 different countries on 5 continents, and enrolled participants of both sexes from birth to 100 years of age. Baseline serum 25(OH)D concentrations were determined in 38 of 46 trials: mean baseline 25(OH)D concentration ranged from 18.9 to 90.9 nmol/L (to convert to ng/mL, divide by 2.496). Forty-five studies administered oral vitamin D₃ to participants in the intervention arm, while 1 study administered oral 25(OH)D. Vitamin D was given as monthly to 3monthly bolus doses in 13 studies; as weekly doses in 7 studies; as daily doses in 24 studies; and as a combination of bolus and daily doses in 2 studies. Trial duration ranged from 7 weeks to 5 years. Incidence of ARI was primary or co-primary outcome for 25 studies, and a secondary outcome for 21 studies.

Risk of Bias Within Studies

Details of the risk of bias assessment are provided in supplementary Table S2. Five trials were assessed as being at unclear risk of bias due to high loss to follow-up. In

the trial by Laaksi and colleagues,²³ 37% of randomised participants were lost to follow-up. In the trial by Dubnov-Raz and colleagues,¹³ 52% of participants did not complete all symptom questionnaires. In the unpublished trial by Reyes and colleagues,⁵⁷ loss to follow-up ranged from 33% to 37% across the three study arms, and in the unpublished trial by Golan-Tripto and colleagues,⁵⁸ 50% of participants were lost to follow-up. Finally, in the trial by Huang and colleagues,⁵⁵ we detected uncertainty around blinding of outcome assessment within the study team; methodology for dealing with incomplete data, and selective outcome reporting, which we were unable to resolve with the authors. All other trials were assessed as being at low risk of bias for all seven aspects assessed.

Overall Results, Primary Outcome

For the primary comparison of any vitamin D supplement vs. placebo control, supplementation did not result in a statistically significant reduction in the proportion of participants experiencing at least one ARI (odds ratio [OR] 0.94, 95% CI 0.88 to 1.00, P=0.57; 61,589 participants in 40 studies; Figure 2, Table 2; Cates Plot, Figure S1). Between-trial heterogeneity was modest: $I^2 = 26.4\%$ (P for heterogeneity 0.07).

For the secondary comparison of higher- vs. lower-dose vitamin D, we observed no statistically significant difference in the proportion of participants with at least one ARI (OR 0.87, 95% CI 0.73 to 1.04; 3,047 participants in 11 studies; I^2 0.0%, P for heterogeneity 0.50; Figure S2).

Sub-group Analyses, Primary Outcome

To investigate reasons for the observed heterogeneity of effect for the primary comparison of any vitamin D supplement vs. placebo control, we stratified this analysis by two participant-level factors (baseline vitamin D status and age) and by four trial-level factors (dose frequency, dose size, trial duration, and airway disease comorbidity). Results are presented in Table 2 and Figures S3-S8. No statistically significant effect of vitamin D was seen for participants with baseline 25(OH)D <25 nmol/L (OR 0.98, 95% CI 0.80 to 1.20; 3,806 participants in 22 studies), 25-49.9 nmol/L (OR 1.03, 95% CI 0.94 to 1.13; 11,618 participants in 31 studies), 50-74.9

nmol/L (OR 0.90, 95% CI 0.80 to 1.02; 11,214 participants in 32 studies), or ≥75 nmol/L (OR 0.97, 95% CI 0.87 to 1.07; 11,815 participants in 28 studies; Figure S3). A statistically significant protective effect of vitamin D was seen for participants aged 1.00-15.99 years (OR 0.74, 95% CI 0.60 to 0.92; 11,944 participants in 16 studies), but not in participants aged <1 year (OR 0.95, 95% CI 0.82 to 1.10; 5,697 participants in 5 studies), 16.00-64.99 years (OR 0.96, 95% CI 0.85 to 1.08; 9,636 participants in 22 studies), or ≥65.00 years (OR 0.96, 95% CI 0.90 to 1.02; 19,140 participants in 17 studies; Figure S7). With regard to dosing frequency, a statistically significant protective effect was seen for trials where vitamin D was given daily (OR 0.84, 95% CI 0.73 to 0.97; 21,552 participants in 21 studies), but not for trials in which it was given weekly (OR 0.97, 95% CI 0.88 to 1.06; 12,789 participants in 7 studies), or monthly to 3-monthly (OR 0.98, 95% CI 0.93 to 1.03; 27,248 participants in 12 studies; Figure S4). Statistically significant protective effects of the intervention were also seen in trials where vitamin D was administered at daily equivalent doses of 400-1000 IU (OR 0.70, 95% CI 0.55 to 0.89; 2,305 participants in 10 studies), but not where the daily dose equivalent was <400 IU (OR 0.76, 95% CI 0.41 to 1.41; 2,133 participants in 2 studies), 1001-2000 IU (OR 0.97, 95% CI 0.92 to 1.01; 49,457 participants in 19 studies), or >2000 IU (OR 1.05, 95% CI 0.84 to 1.31; 6,906 participants in 7 studies; Figure S5). Statistically significant protective effects were also seen for trials with a duration of ≤12 months (OR 0.85, 95% CI 0.76 to 0.95; 24,678 participants in 32 studies) but not in those lasting >12 months (OR 0.99, 95% CI 0.95 to 1.04; 36.911 participants in 8 studies; Figure S6).

Statistically significant protective effects of vitamin D were not seen in trials that exclusively enrolled participants with asthma, or trials that exclusively enrolled participants with COPD, or trials that were not restricted to participants with either asthma or COPD (Figure S8).

Multivariable Meta-Regression Analysis

Multivariable meta-regression analysis of trial-level sub-groups did not identify any statistically significant interactions (P values for interaction <0.05) between allocation to vitamin D vs. placebo and dose frequency, dose size, trial duration or participant age (Table S3).

Secondary outcomes

Meta-analysis of secondary outcomes was performed for results of placebo-controlled trials only (i.e. not for RCTs that compared higher- vs. lower-dose vitamin D). Results are presented in Table 3. Overall, without consideration of participant- or trial-level factors, vitamin D supplementation did not have a statistically significant effect on the proportion of participants with one or more URI, LRI, hospitalisations or emergency department attendances for ARI, death due to ARI or respiratory failure, courses of antimicrobials for ARI, work/school absences due to ARI, serious adverse events of any cause, death due to any cause, or episodes of hypercalcaemia or renal stones.

Risk of bias across studies

A funnel plot for the proportion of participants experiencing at least one ARI (Figure S9) showed left-sided asymmetry, confirmed with an Egger's regression test⁵⁹ (P=0.002). This might reflect heterogeneity of effect across trials, or publication bias arising from omission of small trials showing non-protective effects of vitamin D from the meta-analysis.⁶⁰ Given the latter possibility, the quality of the body of evidence contributing to analyses of the primary efficacy outcome and major secondary outcomes was downgraded to moderate (Table S4).

Sensitivity Analyses

Results of exploratory sensitivity analyses are presented in Table S5. Meta-analysis of the proportion of participants in placebo-controlled trials experiencing at least one ARI, excluding 4 studies assessed as being at unclear risk of bias,^{13,23,55,57} did not reveal a statistically significant protective effect of any vitamin D supplementation (OR 0.95, 95% CI 0.90 to 1.01; 60,958 participants in 36 studies), consistent with the main analysis. Similarly, a sensitivity analysis for the same outcome, excluding 19 placebo-controlled trials that investigated ARI as a secondary outcome, did not show a statistically significant protective effect (OR 0.90, 95% CI 0.79 to 1.02; 9,975 participants in 21 studies).

Exploratory analysis

Due to the relatively low level of between-trial heterogeneity ($I^2 = 26.4\%$) we analysed the primary outcome using a fixed effects model, which yielded a very similar effect estimate (P=0.047).

Discussion

This update to our 2021 meta-analysis of RCTs of vitamin D supplementation for the prevention of ARI includes new primary outcome data from an additional 15,598 participants in 3 studies completed since May 2020, bringing the total number contributing data to 64,086 participants in 46 trials. The point estimate of the overall effect of vitamin D supplementation on ARI risk obtained in the current analysis (0.94) is similar to that yielded by our previous meta-analysis (0.92). However, in contrast to our previous work, ⁴⁷ the 95% CI for this effect now spans 1.00. Although statistically significant protection was seen within some trial subsets (daily dosing trials, trials that administered 400-1000 IU/day, trials conducted for 12 months or less and trials in participants aged 1.00-15.99 years), meta-regression analysis did not yield formal evidence to suggest that effects of vitamin D were modified by any of these factors.

Heterogeneity of results from the current meta-analysis is somewhat lower than that obtained from our previous meta-analysis (I^2 26.4% vs. 35.6%, respectively). This difference suggests that greater confidence may be placed in the findings of the current analysis vs. our previous one. It is possible that the previous overall finding of a protective effect of any vitamin D supplement was driven by small study effects, as evidenced by left-sided asymmetry shown in the funnel plot (Figure S9).⁶⁰

The current study has several strengths: it contains the latest aggregate RCT data available worldwide, including stratified data for subgroups of baseline vitamin D status and age, new data from a very large trial (n=15,804)¹⁰ and as yet unpublished data, which together represent 10.7% of the overall model weight. The larger sample size provides improved statistical power to perform subgroup analyses and interrogate heterogeneity of effects across trials. Nevertheless, formal demonstration of effect modification is challenging and will likely require even larger sample sizes.

Our work also has limitations: some trials did not respond to our invitation to contribute data for meta-analysis (Figure 1 and Table S1), at least one of which reported protective effects of vitamin D against ARI,⁶¹ therefore potentially biasing our results towards the null. We meta-analysed aggregate (trial-level) data, rather than individual participant data. However, we did contact authors to get unpublished estimates of effect that were stratified by pre-defined baseline 25(OH)D levels and age, harmonised across studies: thus, we were able to obtain accurate data for the major participantlevel potential effect-modifiers of interest. As with our previous update to synthesis of this research question, there are still relatively few RCTs that have compared effects of lower- vs. higher-dose vitamin D. Paucity of data in this area limited our power for this secondary comparison. We lacked the data to investigate race/ethnicity and obesity as potential effect-modifiers. We also could not account for other factors that might influence the efficacy of vitamin D supplements for ARI prevention (e.g., taking the supplement with or without food, calcium intake, vitamin A status) or secular trends that might influence trial findings, such as the increased societal use of vitamin D supplements:⁶² concurrent use of supplements containing vitamin D by participants randomised to control would effectively render these as high- vs. low-dose trials and potentially drive results toward the null. Another potential limitation is illustrated by the funnel plot, which suggests that the overall effect size may have been over-estimated due to publication bias; we have attempted to mitigate this problem by inclusion of data from unpublished studies identified by searching clinicaltrials.gov where this was obtainable.

In summary, this updated meta-analysis of data from RCTs of any vitamin D supplementation for the prevention of ARI yielded a similar point estimate for the overall effect of vitamin D supplementation on ARI risk to that obtained previously, but the 95% CI for this effect now spans 1.00, indicating no statistically significant protection.

Acknowledgements

This study was conducted without external funding. ARM is supported by the United Kingdom Office for Students. The views expressed are those of the authors and not necessarily those of Barts Charity or the Office for Students. Sources of support for individual trials are detailed in Supplementary Material. We thank all the people who participated in primary randomised controlled trials, and the teams who conducted them.

Author Contributions

DAJ and ARM wrote the study protocol and designed statistical analyses. DAJ, CAC and ARM assessed eligibility of studies for inclusion. DAJ, ARM, CAC and JDS performed risk of bias assessments. DAJ and ARM had access to, and verified, the underlying data from all original research articles. Statistical analyses were done by DAJ; results were checked and verified by JDS. DAJ and ARM wrote the first draft of the report. All authors revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

Competing Interests

All authors have completed the ICMJE uniform disclosure form. ARM reports grants from the Fischer Family Trust, Pharma Nord Ltd, DSM Nutritional Products Ltd, the AIM Foundation, Cytoplan Ltd, and Thornton & Ross Ltd outside the submitted work. CG reports grants from the Health Technology Assessment Program of the UK National Institute of Health Research during conduct of the study. WJ reports grants from Chiesi and Astra Zeneca outside the submitted work. REN reports grants from the Australian National Health and Medical Research Council during the conduct of the study. No other author has had any financial relationship with any organisations that might have an interest in the submitted work in the previous three years. No other author has had any other relationship, or undertaken any activity, that could appear to have influenced the submitted work.

Transparency Declaration

DAJ and ARM are the manuscript's guarantors and they affirm that this is an honest, accurate, and transparent account of the study being reported and that no important aspects of the study have been omitted. All analyses were pre-specified in the study protocol.

Data Sharing: the study dataset is available from <u>d.a.jolliffe@qmul.ac.uk</u>.

Figure 1: Flow chart of study selection



Figure 2: Forest plot of placebo-controlled RCTs reporting proportion of participants experiencing 1 or more acute respiratory infection.

1 at Author (min)	Veer	Proportion with \geq 1 ARI,	Proportion with ≥1 ARI,	Odds	%
1st Author (trial)	Year	intervention group(%)	control group(%)	Hatio (95% CI)	weight
Li-Ng	2009	32/81(39.5)	33/76(43.4)	- 0.85 (0.45, 1.61)	0.91
Laaksi	2010	39/80(48.8)	54/84(64.3)	0.53 (0.28, 0.99)	0.94
Manaseki-Holland	2010	97/224(43.3)	126/229(55)	0.62 (0.43, 0.90)	2.41
Urashima	2010	68/167(40.7)	69/167(41.3)	0.98 (0.63, 1.51)	1.82
Majak	2011	4/24(16.7)	11/24(45.8) (=i	0.24 (0.06, 0.90)	0.22
Trilok-Kumar	2011	438/1034(42.4)	458/1030(44.5)	0.92 (0.77, 1.09)	7.04
Bergman	2012	26/62(41.9)	39/62(62.9)	0.43 (0.21, 0.88)	0.72
Camargo*	2012	13/40(32.5)	15/29(51.7)	0.45 (0.17, 1.20)	0.40
Lehouck	2012	30/86(34.9)	29/89(32.6)	→ 1.11 (0.59, 2.07)	0.94
Manaseki-Holland	2012	260/1506(17.3)	245/1505(16.3)	1.07 (0.89, 1.30)	6.33
Murdoch	2012	154/161(95.7)	155/161(96.3)	→ 0.85 (0.28, 2.59)	0.31
Marchisio	2013	26/58(44.8)	38/58(65.5)	0.43 (0.20, 0.90)	0.67
Rees	2013	303/399(75.9)	276/360(76.7)	0.96 (0.69, 1.34)	2.85
Goodall	2014	70/258(27.1)	80/234(34.2)	0.72 (0.49, 1.05)	2.26
Grant	2014	94/157(59.9)	53/80(66.3)	0.76 (0.43, 1.33)	1.15
Tran	2014	185/397(46.6)	96/197(48.7) -	0.92 (0.65, 1.29)	2.76
Urashima	2014	32/148(21.6)	17/99(17.2)	→ 1.33 (0.69, 2.56)	0.87
Dubnov-Raz	2015	10/14(71.4)	10/11(90.9)	→ 0.25 (0.02, 2.65)	0.07
Martineau (ViDiAs)	2015	85/125(68)	93/125(74.4)	0.73 (0.42, 1.27)	1.20
Martineau (ViDiCO)	2015	76/122(62.3)	75/118(63.6)	- 0.95 (0.56, 1.60)	1.31
Martineau (ViDiFlu)**	2015	13/22(59.1)	13/24(54.2)	→ 1.22 (0.38, 3.93)	0.28
Simpson	2015	16/18(88.9)	14/16(87.5)		0.09
Denlinger	2016	110/201(54.7)	93/207(44.9)	➡ 1.48 (1.00, 2.19)	2.21
Gupta	2016	39/156(25)	36/158(22.8)	- 1.13 (0.67, 1.90)	1.33
Tachimoto	2016	4/54(7.4)	5/35(14.3)	- 0.48 (0.12, 1.93)	0.20
Loeb	2018	50/577(8.7)	43/576(7.5)	- 1.18 (0.77, 1.80)	1.91
Shimizu	2018	41/110(37.3)	43/105(41)	0.86 (0.50, 1.48)	1.20
Aloia	2019	76/130(58.5)	72/130(55.4)	- 1.13 (0.69, 1.85)	1.47
Arihiro	2019	19/115(16.5)	30/108(27.8)	0.51 (0.27, 0.98)	0.88
Hauger	2019	36/77(46.8)	25/41(61)	0.56 (0.26, 1.21)	0.63
Bischoff-Ferrari	2020	647/1076(60.1)	652/1081(60.3)	0.99 (0.84, 1.18)	7.12
Camargo	2020	1882/2539(74.1)	1855/2517(73.7)	1.02 (0.90, 1.16)	9.53
Ganmaa	2020	3783/4401(86)	3793/4418(85.9)	1.01 (0.89, 1.14)	9.86
Mandlik	2020	92/116(79.3)	99/121(81.8)	- 0.85 (0.45, 1.62)	0.89
Pham***	2020	5253/8000(65.7)	5310/8000(66.4)	0.97 (0.91, 1.03)	13.22
Rake	2020	73/395(18.5)	65/392 (16.6)	- 1.14 (0.79, 1.65)	2.44
Ducharme	2022	1/18(5.6)	3/15(20)	→ 0.24 (0.02, 2.54)	0.07
Huang	2022	1/135(0.7)	5/113(4.4)	0.16 (0.02, 1.40)	0.08
Camargo	2023	899/7676(11.7)	930/7641(12.2)	0.96 (0.87, 1.06)	11.23
NCT02046577 (Reyes / Borzutsky) Unpublished	125/133 (94)	59/61(96.7)	→ 0.53 (0.11, 2.57)	0.16
Overall (I-squared = 26.4%, p = 0	.066)		d d d d d d d d d d d d d d d d d d d	0.94 (0.88, 1.00)	100.00
NOTE: Weights are from random	effects analysis	;			
			 .125 .25 .5 1	2	

*Proportions for this trial were corrected for cluster randomisation using the calculated design effect of 3.49. **This analysis includes data from the subset of ViDiFlu trial participants who were randomised to vitamin D vs. placebo control; correction for cluster randomisation was not possible due to the lack of power. ***For this trial, participants were asked to report the occurrence of ARI during the one month prior to completing each annual survey (max surveys=5). The numerator is the number of participants who reported an ARI on at least one survey. The ARI outcomes for participants who completed fewer than 5 surveys and who did not report an ARI (N=2239; 14%) were estimated based on the % affected among those who completed all 5 surveys (N=12152; 76%).

Favours vitamin D Favours placebo

Table 1: Characteristics of trials and their participants

Study first author, year	Setting	Participants	Mean age, years (s.d.) [range]	Male: Female	25(OH)D assay, EQA scheme	Mean baseline 25(OH)D, nmol/L (s.d.)	Baseline 25(OH)D <25 nmol/L (%)	Mean attained 25(OH)D, intervention arm, nmo/L (s.d.)	Intervention: Control (total)	Oral dose of vitamin D_3 , intervention arm	Control	Trial duration	ARI definition	ARI primary or secondary outcome?	N contributing data / N randomised (%)
Li-Ng 2009 ²⁶	USA	Healthy adults	57.9 (13.6) [21.4 - 80.6]	34:128	RIA (DiaSorin), DEQAS	63.7 (25.5)	3/150 (2.0)	88.5 (23.2)	84:78 (162)	50 µg daily	Placebo	3 mo	URI: ≥2 URI symptoms in absence of allergy symptoms	Primary	157/162 (96.9)
Urashima 2010 ⁴⁶	Japan	Schoolchildren	10.2 (2.3) [6.0 – 15.0]	242:188	Not determined	Not determined	Not determined	d Not determined	217:213 (430)	30 µg daily	Placebo	4 mo	URI: influenza A/B diagnosed by RIDT or RIDT-negative ILI	Primary	334/430 (77.7)
Manaseki- Holland 2010 ³⁰	Afghanistan	Pre-school children with pneumonia	1.1 (0.8) [0.1 – 3.3]	257:196	Not determined	Not determined	Not determined	d Not determined	224:229 (453)	2.5 mg bolus once	Placebo	3 mo	LRI: repeat episode of pneumonia – age-specific tachypnoea without wheeze	Secondary	453/453 (100.0)
Laaksi 2010 ²³	Finland	Military	19.1 (0.6) [18.0 – 21.0]	164:0	EIA (IDS OCTEIA)	75.9 (18.7)	0/73 (0.0)	71.6 (22.9)	80:84 (164)	10 µg daily	Placebo	6 mo	ARI: medical record	Primary	164/164
Majak 2011	Poland	Children with	10.9 (3.3)	32:16	RIA (BioSource	88.9 (38.2)	0/48 (0.0)	37.6 (13.1)	24:24 (48)	12.5 µg daily	Placebo	6 mo	ARI: self-report	Secondary	48/48 (100.0)
Trilok- Kumar 2011 ⁶³	India	Low birthweight infants	[0.0 – 17.0] 0.1 (0.0) [0.0 – 0.3]	970:1109		Not determined	Not determined	d 55.0 (22.5)	1039:1040 (2079)	35 µg weekly	Placebo	6 mo	ARI: medical record diagnosis of events causing hospitalisation	Secondary	2064/2079 (99.3)
Lehouck 2012 ²⁵	Belgium	Adults with COPD	67.9 (8.3) [48.0 – 86.0]	145:37	RIA (Diasorin), DEQAS	49.8 (29.2)	31/182 (17.0)	130.0 (44.7)	91:91 (182)	2.5 mg bolus monthly	Placebo	1 yr	URI: self-report	Secondary	175/182 (96.2)
Manaseki- Holland 2012 ²⁹	Afghanistan	Infants	0.5 (0.3) [0.0 – 1.0]	1591:1455		Not determined	Not determined	d 32.7 (17.1)	1524:1522 (3046)	2.5 mg bolus 3- monthly	Placebo	1.5 yr	LRI: pneumonia confirmed by chest radiograph	Primary	3011/3046 (98.9)
Camargo 2012 ⁹	Mongolia	3 rd /4 th grade schoolchildren	10.0 (0.9) [7.0 – 12.7]	129:118	LC-MS/MS, DEQAS	18.9 (9.7)	192/245 (78.4)	49.1 (15.1)	143:104 (247)	7.5 µg daily	Placebo	7 wk	ARI: parent- reported 'chest infections or colds'	Secondary	244/247 (98.8)
Murdoch 2012 ³⁶	New Zealand	Healthy adults	48.1 (9.7) [18.0 – 67.6]	81:241	LC-MS/MS, DEQAS	72.1 (22.1)	5/322 (1.6)	123.6 (27.5)	161:161 (322)	2 x 5 mg bolus monthly then 2.5 mg bolus monthly	Placebo	1.5 yr	URI: assessed with symptom score	Primary	322/322 (100.0)
Bergman 2012 ⁶⁴	Sweden	Adults with increased susceptibility to ARI	53.1 (13.1) [20.0 – 77.0]	38:102	CLA (DiaSorin), DEQAS	49.3 (23.2)	15/131 (11.45)	94.9 (38.1)	70:70 (140)	100 µg daily	Placebo	1 yr	URI: assessed with symptom score	Secondary	124/140 (88.6)
Marchisio 2013 ³²	Italy	Children with recurrent acute otitis media	2.8 (1.0) [1.3 – 4.8]	64:52	CLA (DiaSorin), ISO9001	65.3 (17.3)	2/116 (1.7)	90.3 (21.1)]	58:58 (116)	25 µg daily	Placebo	6 mo	URI: doctor- diagnosed acute otitis media	Primary	116/116 (100.0)
Rees 2013 ³⁶	USA	Adults with previous colorectal adenoma	61.2 (6.6) [47.1 – 77.9]	438:321 ^[a]	RIA (IDS), DEQAS	62.5 (21.3)	0/759 (0.0)	186.9 (455.1)	399:360 (759)	25 µg daily	Placebo	13 mo (average)	URI: assessed from daily symptom diary	Secondary	759/759 (100.0)
Tran 2014 ⁴⁴	Australia	Healthy older adults	71.7 (6.9) [60.3 – 85.2]	343:301	CLA (DiaSorin), DEQAS	41.7 (13.5)	66/643 (10.3)	71.0 (19.6)	430:214 (644)	0.75 mg bolus <i>vs.</i> 1.5 mg bolus monthly	Placebo	1 yr	URI: self-reported cold	Secondary	594/644 (92.2)
Goodall 2014 ¹⁷	Canada	Healthy university students	19.6 (2.2) [17.0 – 33.0]	218:382	Not determined	Not determined	Not determined	d Not determined	300:300 (600)	0.25 mg weekly (2x2 factorial with gargling)	Placebo	8 wk	URI: self-reported cold	Primary	492/600 (82.0)
Urashima 2014 ⁴⁵	Japan	High school students	16.5 (1.0) [15.0 – 18.0]	162:85	Not determined	Not determined	Not determined	d Not determined	148:99 (247)	50 µg daily	Placebo	2 mo	URI: influenza A diagnosed by RIDT or RIDT-negative ILI	Primary	247/247 (100.0)
Grant 2014 ¹⁸	New Zealand	Pregnant women and offspring	Offspring unborn at baseline	0:260 (pregnant women) 121:128 (offspring)	LC-MS/MS, DEQAS	54.8 (25.8)	30/200 (15.0)	92.9 (41.6)	173:87 (pregnant women, 260) 164:85 (offspring, 249)	Pregnant women: 25 µg vs. 50 µg daily. Offspring: 10 µg vs. 20 µg daily	Placebo	9 mo (3 mo in pregnancy + 6 mo in infancy)	ARI: doctor- diagnosed ARI precipitating primary care consult	Secondary	236/260 (90.8)

Study first author, year	Setting	Participants	Mean age, years (s.d.) [range]	Male: Female	25(OH)D assay, EQA scheme	Mean baseline 25(OH)D, nmol/L (s.d.)	Baseline 25(OH)D <25 nmol/L (%)	Mean attained 25(OH)D, intervention arm, nmo/L (s.d.)	Intervention: Control (total)	Oral dose of vitamin D ₃ , intervention arm	Control	Trial duration	ARI definition	ARI primary or secondary outcome?	N contributing data / N randomised (%)
Martineau 2015a ³⁴ [ViDiCO]	UK	Adults with COPD	64.7 (8.5) [40.0 – 85.0]	144:96	LC-MS/MS, DEQAS	46.1 (25.7)	50/240 (20.8)	67.3 (27.5)	122:118 (240)	3 mg bolus 2- monthly	Placebo	1 yr	URI: assessed from daily symptom diary	Co-primary	240/240 (100.0)
Martineau 2015b ³⁵ [ViDiAs]	UK	Adults with asthma	47.9 (14.4) [16.0 – 78.0]	109:141	LC-MS/MS, DEQAS	49.6 (24.7)	36/250 (14.4)	69.4 (21.0)	125:125 (250)	3 mg bolus 2- monthly	Placebo	1 yr	URI: assessed from daily symptom diary	Co-primary	250/250 (100.0)
Martineau 2015c ³³ [ViDiFlu]	UK	Older adults and their carers	67.1 (13.0) [21.4 – 94.0]	82:158	LC-MS/MS, DEQAS	42.9 (23.0)	60/240 (25.0)	84.8 (24.1)	137:103 (240)	Older adults: 2.4 mg bolus 2- monthly + 10 µg daily Carers: 3 mg 2- monthly	Older adults: placebo + 10 µg daily Carers: placebo	1 yr	URI & LRI, both assessed from daily symptom diary	Co-primary	240/240 (100.0)
Simpson 2015 ⁴²	Australia	Healthy adults	32.2 (12.2) [18.0 – 52.0]	14:20	LC-MS/MS, DEQAS	67.9 (23.0)	0/33 (0.0)	Not determined	18:16 (34)	0.5 mg weekly	Placebo	17 wk	ARI assessed with symptom score	Primary	34/34 (100.0)
Dubnov- Raz 2015 ¹³	Israel	Adolescent swimmers with vitamin D insufficiency	15.2 (1.6) [12.9 – 18.6]	34:20	RIA (DiaSorin), DEQAS	60.4 (11.9)	0/54 (0.0)	73.7 (16.6)	27:27 (54)	50 μg daily	Placebo	12 wk	URI assessed with symptom score	Primary	25/54 (46.3)
Denlinger 2016 ¹²	USA	Adults with asthma	39.2 (12.9) [18.0 – 85.0]	130:278	CLA (DiaSorin), VDSP	47.0 (16.9)	55/408 (13.5)	104.3 (32.4)	201:207 (408)	2.5 mg bolus then 100 µg daily	Placebo	28 wk	URI assessed with symptom score	Secondary	408/408 (100.0)
Tachimoto 2016 ⁴³	Japan	Children with asthma	9.9 (2.3) [6.0 – 15.0]	50:39	RIA (DiaSorin), CAP	74.9 (24.6)	1/89 (1.1)	85.7 (24.5)	54:35 (89)	20 µg daily, first 2 mo.	Placebo	6 mo	URI: assessed with symptom score	Secondary	89/89 (100.0)
Ginde, 2016 ¹⁶	USA	Institutionalised older adults	80.7 (9.9) [60.0 – 95.0]	45:62	LC-MS/MS, VDSP	57.3 (22.7)	12/107 (11.2)	Not determined	55:52 (107)	2.5 mg bolus monthly + ≤25 µg per day equivalent	Placebo + 10-25 µg per day equivalent	1 yr	ARI: medical record diagnosis	Primary	107/107 (100.0)
Gupta 2016 ¹⁹	India	Children with pneumonia	1.4 (1.1) [0.5 – 5.0]	226:98	RIA (Immunotech SAS/ DiaSorin)	43.9 (33.4)	104/312 (33.3)	64.1 (43.9)	162:162 (324)	2.5 mg bolus, single dose	Placebo	6 mo	Physician confirmed recurrent pneumonia	Co-primary	314/324 (96.9)
Aglipay 2017 ^₄	Canada	Healthy children	2.7 (1.5) [1.0 – 5.0]	404:296	CLA (Roche ELECSYS)	90.9 (20.9)	1/703 (0.1)	High dose: 121.6 (2.2); Low dose: 91.9 (1.7)	349:354	50 µg daily	10 µg daily	4-8 mo (mean 6.3 mo)	URI: lab confirmed	Primary	699/703 (99.4)
Arihiro 2019 ⁶	Japan	Adults with diagnosis of inflammatory bowel disease	44.5 (13.2) [18.0 – 82.0]	146:91	RIA (Diasorin)	58.6 (22.0)	5/223 (2.2)	80.4 (21.5)	119:118 (237)	12.5 µg daily	Placebo	6 mo	Lab confirmed influenza	Primary	223/237 (94.1)
Hibbs 2018	USA	African American preterm infants	Offspring unborn at baseline	166:133 ^[b]	RIA	55.4 (22.2)	0/300 (0.0)	95.0 (21.2)	153:147 (300)	10 μg daily, regardless of dietary intake	10 μg daily, only if dietary intake was <5 μg daily	1 yr	ARI: self-reported URI/LRI	Secondary	300/300 (100.0)
Lee 2018 ²⁴	USA	Children and young adults with sickle cell disease	9.9 (3.9) [3.0 – 20.0]	30:32	LC-MS/MS, DEQAS	35.7 (16.5)	18/62 (29.0)	92.4 (23.7)	31:31 (62)	2.5 mg bolus monthly	0.3 mg monthly	2 yrs	Self-reported respiratory events, including ARI	Primary	62/62 (100.0)
Loeb 2018	Vietnam	Healthy children and adolescents	8.5 (4.0) [3.0 – 17.0]	621:679	CLA (DiaSorin), DEQAS	65.5 (16.8)	5/1153 (43.4)	91.8 (23.6)	650:650 (1300)	0.35 mg weekly	Placebo	8 mo	RT-PCR confirmed influenza A or B	Primary	1153/1300 (88.7)
Rosendahl 2018 40	Finland	Healthy infants	Offspring unborn at baseline	495:492	CLA (IDS-iSYS) VDSP	81.5 (25.9)	0/879 (0.0)	117.7 (26.1)	492:495 (987)	30 µg daily	10 µg daily	2 yrs	Parent reported infections, including ARI	Co-primary	897/987 (90.9)
Shimizu 2018 41	Japan	Healthy adults	53.1 (6.7) [45.0 – 74.0]	82:170	RIA (DiaSorin)	48.9 (13.5)	1/214 (0.5)	114.6 (32.7)	126:126 (252)	10 µg daily (25[OH] D) ^[c]	Placebo	4 mo	URI: self-reported	Primary	215/252 (85.3)
Aloia 2019 ⁵	USA	Healthy African American women aged over 60 years	69.0 (5.3) [65.4 – 72.5]	0:260	LC-MS/MS, NIST	54.4 (16.7)	9/258 (3.5)	117.0 (28.0)	130:130 (260)	50 µg daily	Placebo	3 mo	ARI: self-reported cold/flu	Secondary	260/260 (100.0)
Hauger 2019 ²⁰	Denmark	Healthy children	6.6 (1.5) [4.0 – 8.0]	61:69	LC-MS/MS, DEQAS	56.8 (12.5)	0/118 (0.0)	20 µg arm: 75.8 (11.5) 10 ug arm: 61.8 (10.6)	43:44:43 (130)	20 µg / 10 µg daily	Placebo	5 mo	ARI: self-reported	Secondary	118/130 (90.8)

Study first author, year	Setting	Participants	Mean age, years (s.d.) [range]	Male: Female	25(OH)D assay, EQA scheme	Mean baseline 25(OH)D, nmol/L (s.d.)	Baseline 25(OH)D <25 nmol/L (%))	Mean attained 25(OH)D, intervention arm, nmo/L (s.d.)	Intervention: Control (total)	Oral dose of vitamin D ₃ , intervention arm	Control	Trial duration	ARI definition	ARI primary or secondary outcome?	N contributing data / N randomised (%)
Bischoff- Ferrari 2020 8	Switzerland, France, Germany, Portugal, and Austria	Older adults	74.9 (4.4) [70.0 – 95.0]	826:1331	LC-MS/MS, DEQAS	55.9 (21.0)	143/2140 (6.7)	93.8 (28.2)	1076:1081	50 µg daily (2x2x2 factorial with omega-3 fatty acid supplementation and strength- training exercise)	Placebo	3 yrs	ARI: self-reported and verified by independent physician	Co-primary	2157/2157 (100.0)
Camargo 2020 ¹¹	New Zealand	Older adults	66.4 (8.3) [50.0 –84.0]	2935:2121	LC-MS/MS, DEQAS	63.4 (23.6)	89/5056 (1.8)	135.0 (39.9)	2558:2552 (5110)	5 mg bolus loading dose; then 2.5 mg bolus monthly	Placebo	3 yrs	ARI: self-reported cold/flu	Secondary	5056/5110 (98.9)
Ganmaa, 2020 ⁶⁵	Mongolia	Healthy school children	9.4 (1.6) [6.0 – 13.0]	4485:4366	EIA (Biomerieux), DEQAS	29.7 (10.5)	2813/8851 (31.8)	77.4 (22.7)	4418:4433 (8851)	0.35 mg weekly	Placebo	3 yrs	ARI: self-reported	Secondary	8851/8851 (100.0)
Mandlik 2020 ³¹	India	Healthy children	8.1 (1.2) [6.0 – 12.0]	158:127	EIA (DLD diagnostics)	58.9 (10.9)	0/237 (0.0)	80 (23.3)	135:150 (285)) 25 µg daily + 500 mg calcium	Placebo	6 mo	URI: self-reported	Secondary	244/285 (85.6)
Pham 2020 66	Australia	Older adults	69.3 (5.5) [60.0 – 86.0]	8678:7322	LC-MS/MS, VDSP	Not determined	Not determined	l 114.8 (30.3) ^[d]	8000:8000 (16000)	1.5 mg bolus monthly	Placebo	5 yrs	ARI: self-reported	Secondary	16,000/16,000 (100.0)
Rake 2020	England	Healthy older adults	72.2 (4.9) [65.0 – 84.0]	408:379	CLA (Cobas 6000 Roche)	50.2 (27.1)	127/787 (16.1)	109.2 (33.9)	395:392 (787)) 2.5 mg bolus monthly	Placebo	2 yrs	URI/LRI: GP recorded	Secondary	787/787 (100.0)
Golan- Tripto unpublisheo	Israel	Prematurely born infants	0 (0)	21:29	CLA (DiaSorin)	33.6 (29.7)	19/46 (41.3)	20 µg arm: 78.0 (75.0) 10 ug arm: 81.0 (73.0)	25:25 (50)	20 µg daily	10 µg daily	1 yr	ARI: GP recorded	Secondary	25/50 (50.0)
Reyes unpublished	Chile	Healthy pre- school children	2.2 (0.5) [1.3 – 3.3]	168:135	LC-MS/MS	62.2 (15.5)	1/194 (0.5)	0.14 mg arm: 82.4 (24.5) 0.28 mg arm: 104.6 (52.9)	99:103:101 (303)	0.14 mg / 0.28 mg weekly	Placebo	6 mo	ARI: self-reported	Primary	194/303 (64.0
Ducharme 2022 ⁶⁷	Canada	Healthy adult healthcare workers	40.0 (9.84) [25.0 - 58.0]	02:31	automated chemiluminescence analyzer, DiaSorin LIAISON XL platform	48.9 (21.9)	2/31 (6.1%)	97.7 (27.1)	18:15 (33)	2.5 mg bolus loading dose; then 0.25 mg weekly	Placebo	4 mo	Lab confirmed COVID-19	Primary	33/34 (97.1)
Huang 2022	2 Taiwan	Healthy preschool-age children	3.9 (0.7) [range not reported]	136:112	Not reported	Not reported	0/21 (0.0)	Not determined	135:113 (248) 50 µg daily	Placebo	6 mo	Parent-reported influenza	Primary	248/248 (100.0)
Camargo 2023 ¹⁰	USA	Healthy older adults	68.0 (7.0) [50.0 - 100.4]	7771:8033	LC-MS/MS	76.9 (25.0)	188/15804 (1.2%)	104.3 (29.6)	7905:7899 (15804)	50 µg daily (2x2 factorial with marine n-3 fatty acids)	Placebo	1 yr	ARI: self-reported	Secondary	15013/15804 (95.0)

[a] Sex missing for two participants randomised to intervention arm and subsequently excluded from analysis due to lack of outcome data. [b] Sex missing for one participants. [c] equivalent to 30 ug vitamin D₃.⁶⁸ 1 µg vitamin D₃ = 40 international units (IU); 25(OH)D concentrations reported in ng/ml were converted to nmol/L by multiplying by 2.496. [d] from subset of participants randomised to intervention; for comparison, mean 25(OH)D at follow-up in subset of participants randomised to placebo was 77.5 nmol/L (sd 25.2 nmol/L); 25(OH)D, 25-hydroxyvitamin D; RIDT, rapid influenza diagnostic test; COPD, chronic obstructive pulmonary disease; D₃, vitamin D₃ (cholecalciferol); p.o., *per os* (orally); mo, month; yr, year; wk, week. ARI, acute respiratory infection; CAP, College of American Pathologists, CLA, chemiluminescent assay; DEQAS, Vitamin D External Quality Assessment Scheme; EIA, enzyme immunoassay; EQA, external quality assessment; GP, general practitioner; LC-MS/NS, liquid chromatography tandem-mass spectrometry, RIA, radio-immunoassay; URI, upper respiratory infection; LRI, lower respiratory infection; ILI, influenza-like illness; RIQAS, Randox International Quality Assessment Scheme; VDSP, Vitamin D Standardisation Program of the Office of Dietary Supplements, National Institutes of Health, USA

Table 2: Placebo controlled RCTs: Proportion of participants experiencing at least one acute respiratory infection, overall and stratified by potential effect-modifiers

Potential effect- modifier	No of trials	Proportion with ≥1 ARI, intervention group (%)	Proportion with ≥1 ARI, control group (%)	Odds ratio (95% Cl)	l ² %	P for heterogeneity
Overall	40	15202/31092 (48.9)	15117/30497 (49.6)	0.94 (0.88 to 1.002)	26.4	0.07
Baseline 25(OH)	, nmol/L [[]	a]				
<25	22	1387/1893 (73.3)	1408/1913 (73.6)	0.98 (0.80 to 1.20)	3.6	0.41
25 - 49.9	31	3783/5849 (64.7)	3707/5769 (64.3)	1.03 (0.94 to 1.13)	0.0	0.55
50 - 74.9	32	2237/5749 (38.9)	2142/5465 (39.2)	0.90 (0.80 to 1.02)	8.7	0.33
≥75	28	1530/6045 (25.3)	1503/5899 (25.5)	0.97 (0.87 to 1.07)	0.0	0.83
Dosing frequency	y		·			_
Daily	21	2572/10920 (23.6)	2569/10632 (24.2)	0.84 (0.73 to 0.97)	44.8	0.01
Weekly	7	4483/6439 (69.6)	4450/6350 (70.1)	0.97 (0.88 to 1.06)	0.0	0.44
Monthly or less	12	8147/13733 (59.3)	8098/13515 (59.9)	0.98 (0.93 to 1.03)	0.0	0.57
frequently						
Daily dose equiva	alent, IU ^{LD}		1	a.		
<400	2	451/1074 (42.0)	473/1059 (44.7)	0.76 (0.41 to 1.41)	49.0	0.16
400-1000	10	656/1236 (53.1)	627/1069 (58.7)	0.70 (0.55 to 0.89)	31.2	0.16
1001-2000	19	11494/24790 (46.4)	11612/24667 (47.1)	0.97 (0.92 to 1.01)	1.6	0.44
>2000	7	2291/3462 (66.2)	2250/3444 (65.3)	1.05 (0.84 to 1.31)	37.1	0.15
Trial duration, me	onths	1	1	a	1	
≤12	32	2847/12615 (22.6)	2766/12063 (23.0)	0.85 (0.76 to 0.95)	32.7	0.04
>12	8	12355/18477 (66.9)	12351/18434 (67.0)	0.99 (0.95 to 1.04)	0.0	0.95
Age, yrs ^{laj}		1	1	a	1	
<1.00	5	875/2901 (30.2)	839/2796 (30.0)	0.95 (0.82 to 1.10)	18.7	0.30
1.00-15.99	16	4267/6028 (70.8)	4271/5916 (72.2)	0.74 (0.60 to 0.92)	33.2	0.10
16.00-64.99 ^[c]	22	3138/4894 (64.1)	3090/4742 (65.2)	0.96 (0.85 to 1.08)	12.5	0.29
≥65.00 ^[c]	17	6023/9665 (62.3)	6004/9475 (63.4)	0.96 (0.90 to 1.02)	0.0	0.73
Airway disease	1	i				
Asthma only	4	203/404 (50.2)	202/391 (51.7)	0.73 (0.36 to 1.49)	71.7	0.01
COPD only	2	106/208 (51.0)	104/207 (50.2)	1.01 (0.68 to 1.51)	0.0	0.71
Unrestricted	34	14893/30480 (48.9)	14811/29899 (49.5)	0.94 (0.89 to 1.00)	26.4	0.14

ory [b] Data from two trials that included higher-dose, lower-dose and placebo arms^{44,57} are excluded from this sub-group analysis, since the higher-dose and lower-dose arms spanned the 1,000 IU/day cut-off, rendering them unclassifiable [c] Age-stratified data for one trial¹⁰ were unavailable

Table 3: Placebo-controlled studies: Secondary outcomes

Variables	No of trials	Proportion with ≥1 event, intervention group (%)	Proportion with ≥1 event, control group (%)	Odds ratio (95% CI)	I ² %	P for heterogeneity
Efficacy outcomes						
Upper respiratory infection	32	9396/22244 (42.2)	9341/21734 (43.0)	0.95 (0.91 to 1.01)	4.6	0.39
Lower respiratory infection	16	4040/20915 (19.3)	4049/20739 (19.5)	0.99 (0.93 to 1.04)	0.0	0.58
Emergency department attendance and/or hospital admission due to ARI	20	139/10981 (1.3)	149/10865 (1.4)	0.90 (0.71 to 1.14)	0.0	1.00
Death due to ARI or respiratory failure	35	14/14706 (0.1)	11/14154 (0.1)	1.03 (0.61 to 1.75)	0.0	1.00
Use of antibiotics to treat an ARI	15	2056/8656 (23.8)	2109/8519 (24.8)	0.93 (0.86 to 1.01)	2.0	0.43
Absence from work or school due to ARI	11	378/1545 (24.5)	364/1059 (34.4)	0.91 (0.70 to 1.18)	28.1	0.18
Safety outcomes						
Serious adverse event of any cause	38	1579/22860 (6.9)	1621/22321 (7.3)	0.96 (0.90 to 1.04)	0.0	1.00
Death due to any cause	37	438/22853 (1.9)	397/22288 (1.8)	1.09 (0.95 to 1.25)	0.0	1.00
Hypercalcaemia	23	143/18275 (0.8)	124/17899 (0.7)	1.13 (0.89 to 1.44)	0.0	1.00
Renal stones	23	415/20539 (2.0)	401/20133 (2.0)	1.03 (0.90 to 1.18)	0.0	1.00

* This analysis includes a subset of participants in the trial by Pham et al, who completed symptom diaries.

References

1. Greiller CL, Martineau AR. Modulation of the Immune Response to Respiratory Viruses by Vitamin D. *Nutrients* 2015; **7**(6): 4240-70.

2. Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. *J Steroid Biochem Mol Biol* 2013; **136**: 321-9.

3. Pham H, Rahman A, Majidi A, Waterhouse M, Neale RE. Acute Respiratory Tract Infection and 25-Hydroxyvitamin D Concentration: A Systematic Review and Meta-Analysis. *International journal of environmental research and public health* 2019; **16**(17).

4. Aglipay M, Birken CS, Parkin PC, et al. Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children. *JAMA* 2017; **318**(3): 245-54.

5. Aloia JF, Islam S, Mikhail M. Vitamin D and Acute Respiratory Infections-The PODA Trial. *Open forum infectious diseases* 2019; **6**(9): ofz228.

6. Arihiro S, Nakashima A, Matsuoka M, et al. Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2019; **25**(6): 1088-95.

7. Bergman P, Norlin AC, Hansen S, Bjorkhem-Bergman L. Vitamin D supplementation to patients with frequent respiratory tract infections: a post hoc analysis of a randomized and placebo-controlled trial. *BMC research notes* 2015; **8**: 391.

8. Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial. *JAMA* 2020; **324**(18): 1855-68.

9. Camargo CA, Jr., Ganmaa D, Frazier AL, et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. *Pediatrics* 2012; **130**(3): e561-7.

10. Camargo CA, Jr., Schaumberg DA, Friedenberg G, et al. Effect of daily vitamin D supplementation on risk of upper respiratory infection in older adults: A randomized controlled trial. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2023.

11. Camargo CA, Sluyter J, Stewart AW, et al. Effect of monthly high-dose vitamin D supplementation on acute respiratory infections in older adults: A randomized controlled trial. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2020; **71**: 311-7.

12. Denlinger LC, King TS, Cardet JC, et al. Vitamin D Supplementation and the Risk of Colds in Patients with Asthma. *Am J Respir Crit Care Med* 2016; **193**(6): 634-41.

13. Dubnov-Raz G, Rinat B, Hemila H, Choleva L, Cohen AH, Constantini NW. Vitamin D supplementation and upper respiratory tract infections in adolescent swimmers: a randomized controlled trial. *Pediatric exercise science* 2015; **27**(1): 113-9.

14. Ducharme FM, Tremblay C, Golchi S, et al. Prevention of COVID-19 with oral vitamin D supplemental therapy in essential healthcare teams (PROTECT): protocol for a multicentre, triple-blind, randomised, placebo-controlled trial. *BMJ Open* 2023; **13**(5): e064058.

15. Ganmaa D, Uyanga B, Zhou X, et al. Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. *N Engl J Med* 2020; **383**(4): 359-68.

16. Ginde AA, Blatchford P, Breese K, et al. High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial. *J Am Geriatr Soc* 2017; **65**(3): 496-503.

17. Goodall EC, Granados AC, Luinstra K, et al. Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial. *BMC infectious diseases* 2014; **14**: 273.

18. Grant CC, Kaur S, Waymouth E, et al. Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomised controlled trial. *Acta Paediatr* 2014.

19. Gupta P, Dewan P, Shah D, et al. Vitamin D Supplementation for Treatment and Prevention of Pneumonia in Under-five Children: A Randomized Double-blind Placebo Controlled Trial. *Indian Pediatr* 2016; **53**(11): 967-76.

Hauger H, Ritz C, Mortensen C, et al. Winter cholecalciferol supplementation at 55 degrees N has little effect on markers of innate immune defense in healthy children aged 4-8 years: a secondary analysis from a randomized controlled trial. *Eur J Nutr* 2019; **58**(4): 1453-62.
 Hibbs AM, Ross K, Kerns LA, et al. Effect of Vitamin D Supplementation on Recurrent Wheezing in Black Infants Whee Ware Bern Protorm: The D Wheezin Pandemized Clinical Trial

Wheezing in Black Infants Who Were Born Preterm: The D-Wheeze Randomized Clinical Trial. *JAMA* 2018; **319**(20): 2086-94.

22. Kumar GT, Sachdev HS, Chellani H, et al. Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial. *BMJ* 2011; **342**: d2975.

23. Laaksi I, Ruohola JP, Mattila V, Auvinen A, Ylikomi T, Pihlajamaki H. Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, doubleblinded trial among young Finnish men. *J Infect Dis* 2010; **202**(5): 809-14.

24. Lee MT, Kattan M, Fennoy I, et al. Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. *Blood Adv* 2018; **2**(9): 969-78.

25. Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2012; **156**(2): 105-14.

26. Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. *Epidemiol Infect* 2009; **137**(10): 1396-404.

27. Loeb M, Dang AD, Thiem VD, et al. Effect of Vitamin D supplementation to reduce respiratory infections in children and adolescents in Vietnam: A randomized controlled trial. *Influenza Other Respir Viruses* 2019; **13**(2): 176-83.

28. Majak P, Olszowiec-Chlebna M, Smejda K, Stelmach I. Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection. *J Allergy Clin Immunol* 2011; **127**(5): 1294-6.

29. Manaseki-Holland S, Maroof Z, Bruce J, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. *Lancet* 2012; **379**(9824): 1419-27.

30. Manaseki-Holland S, Qader G, Isaq Masher M, et al. Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial. *Trop Med Int Health* 2010; **15**(10): 1148-55.

31. Mandlik R, Mughal Z, Khadilkar A, et al. Occurrence of infections in schoolchildren subsequent to supplementation with vitamin D-calcium or zinc: a randomized, double-blind, placebo-controlled trial. *Nutr Res Pract* 2020; **14**(2): 117-26.

32. Marchisio P, Consonni D, Baggi E, et al. Vitamin D supplementation reduces the risk of acute otitis media in otitis-prone children. *Pediatr Infect Dis J* 2013; **32**(10): 1055-60.

33. Martineau AR, Hanifa Y, Witt KD, et al. Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). *Thorax* 2015; **70**(10): 953-60.

34. Martineau AR, James WY, Hooper RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. *The lancet Respiratory medicine* 2015; **3**(2): 120-30.

35. Martineau AR, MacLaughlin BD, Hooper RL, et al. Double-blind randomised placebocontrolled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs). *Thorax* 2015; **70**(5): 451-7.

36. Murdoch DR, Slow S, Chambers ST, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. *JAMA* 2012; **308**(13): 1333-9.

37. Pham H, Waterhouse M, Baxter C, et al. The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial. *Lancet Diabetes Endocrinol* 2021; **9**(2): 69-81.

38. Rake C, Gilham C, Bukasa L, et al. High-dose oral vitamin D supplementation and mortality in people aged 65-84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation. *Health Technol Assess* 2020; **24**(10): 1-54.

39. Rees JR, Hendricks K, Barry EL, et al. Vitamin D3 Supplementation and Upper Respiratory Tract Infections in a Randomized, Controlled Trial. *Clin Infect Dis* 2013.

40. Rosendahl J, Valkama S, Holmlund-Suila E, et al. Effect of Higher vs Standard Dosage of Vitamin D3 Supplementation on Bone Strength and Infection in Healthy Infants: A Randomized Clinical Trial. *JAMA pediatrics* 2018; **172**(7): 646-54.

41. Shimizu Y, Ito Y, Yui K, Egawa K, Orimo H. Intake of 25-Hydroxyvitamin D3 Reduces Duration and Severity of Upper Respiratory Tract Infection: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study. *J Nutr Health Aging* 2018; **22**(4): 491-500.

42. Simpson SJ, van der Mei I, Stewart N, Blizzard L, Tettey P, Taylor B. Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT. *BMC Nutrition* 2015; **1**(7).

43. Tachimoto H, Mezawa H, Segawa T, Akiyama N, Ida H, Urashima M. Improved Control of Childhood Asthma with Low-Dose, Short-Term Vitamin D Supplementation: A Randomized, Double-Blind, Placebo-Controlled Trial. *Allergy* 2016.

44. Tran B, Armstrong BK, Ebeling PR, et al. Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial. *Am J Clin Nutr* 2014; **99**(1): 156-61.

45. Urashima M, Mezawa H, Noya M, Camargo CA, Jr. Effects of vitamin D supplements on influenza A illness during the 2009 H1N1 pandemic: a randomized controlled trial. *Food & function* 2014; **5**(9): 2365-70.

46. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *The American journal of clinical nutrition* 2010; **91**(5): 1255-60.

47. Jolliffe DA, Camargo CA, Jr., Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. *Lancet Diabetes Endocrinol* 2021; **9**(5): 276-92.

48. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; **343**: d5928.

49. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons; 2019.

50. Higgins J, Thomas J, Chandler J, et al. Chapter 23: Including variants on randomized trials. *Cochrane Handbook for Systematic Reviews of Interventions version 64 (updated August 2023)* 2023.

51. Harris R, Bradburn M, Deeks J, et al. METAN: Stata module for fixed and random effects meta-analysis, revised 23 Sep 2010. Statistical Software Components S456798. Boston College Department of Economics; 2006.

52. Pearce SH, Cheetham TD. Diagnosis and management of vitamin D deficiency. *BMJ* 2010; **340**: b5664.

53. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced metaanalysis funnel plots help distinguish publication bias from other causes of asymmetry. *J Clin Epidemiol* 2008; **61**(10): 991-6.

54. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; **336**(7650): 924-6.

55. Huang YN, Chi H, Chiu NC, et al. A randomized trial of vitamin D supplementation to prevent seasonal influenza and enterovirus infection in children. *J Microbiol Immunol Infect* 2022; **55**(5): 803-11.

56. Camargo CA, Jr., Schaumberg DA, Friedenberg G, et al. Effect of Daily Vitamin D Supplementation on Risk of Upper Respiratory Infection in Older Adults: A Randomized Controlled Trial. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2024; **78**(5): 1162-9.

57. Reyes ML, Vizcaya C, Borzutzky A, et al. Study of Vitamin D for the Prevention of Acute Respiratory Infections in Children (NCT02046577). https://clinicaltrials.gov/ct2/show/NCT02046577. 58. Golan-Tripto I. The Effect of Vitamin D Administration to Premature Infants on Vitamin D Status and Respiratory Morbidity (NCT02404623). https://clinicaltrials.gov/ct2/show/NCT02404623.

59. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**(7109): 629-34.

60. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011; **343**: d4002.

61. Villasis-Keever MA, Lopez-Alarcon MG, Miranda-Novales G, et al. Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial. *Arch Med Res* 2022; **53**(4): 423-30.

62. Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in Dietary Supplement Use Among US Adults From 1999-2012. *JAMA* 2016; **316**(14): 1464-74.

63. Trilok Kumar G, Sachdev HS, Chellani H, et al. Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial. *BMJ* 2011; **342**: d2975.

64. Bergman P, Norlin AC, Hansen S, et al. Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. *BMJ Open* 2012; **2**(6): e001663.

65. Ganmaa D, Uyanga B, Zhou X, et al. Vitamin D Supplements and Prevention of Tuberculosis Infection and Disease. *N Engl J Med* 2020; **383**: 359-68.

66. Pham H, Waterhouse M, Baxter C, et al. The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial: a randomised controlled trial. *The lancet Diabetes & endocrinology* 2020; **in press**.

67. Hosseini B, Tremblay CL, Longo C, et al. Oral vitamin D supplemental therapy to attain a desired serum 25-hydroxyvitamin D concentration in essential healthcare teams. *Trials* 2022; **23**(1): 1019.

68. Jetter A, Egli A, Dawson-Hughes B, et al. Pharmacokinetics of oral vitamin D(3) and calcifediol. *Bone* 2014; **59**: 14-9.